Warner Pharmaceutical has another variety review! In the first three quarters, the company had 6 product reviews, and 2 won the first one

【Pharmaceutical Network Enterprise News】Domestic pharmaceutical companies are actively carrying out consistency evaluation work in recent years, and continue to receive good news
that products have been evaluated.
On the evening of December 5, 2022, Warner Pharmaceutical announced that recently, the company's ferrous succinate tablets passed the quality and efficacy consistency evaluation
of generic drugs.
Ferrous succinate tablets are suitable for the prevention and treatment of iron deficiency anemia, for the treatment of iron deficiency anemia in adults and children, and to prevent iron
deficiency in pregnant women.
Iron is the building block
of hemoglobin in red blood cells.
When iron deficiency, the amount of hemoglobin synthesized by red blood cells decreases, resulting in a smaller volume of red blood cells, a decrease in oxygen-carrying capacity, and the formation of iron deficiency anemia, oral administration of this product can supplement iron and correct iron deficiency anemia
.
It is understood that the product belongs to the national basic drug catalogue products, and the sales volume has increased
year by year in recent years.
According to Minai.
com, the sales of this product in 2021 will be 107 million yuan, with a sales growth rate of 21.
27%.

At present, in addition to Warner Pharmaceutical, the products of pharmaceutical companies such as Jiudian Pharmaceutical and Jinling Pharmaceutical have previously passed the consistency evaluation
of generic drugs.
Warner Pharmaceutical mentioned in the investor relations activity record form released on December 5 that as of the disclosure date of the company's third quarter report in 2022, the company has 6 products such as polyethylene glycol 4000 powder, montmorillonite powder, fosfomycin tromethamine powder, bismuth potassium citrate capsule, mycophenolate capsule, pantoprazole sodium enteric-coated tablets, etc.
, which have passed the quality and efficacy consistency evaluation of generic drugs, of which fosfomycin tromethamine powder and bismuth potassium citrate capsule are the first products
to be evaluated 。 According to the data, Warner Pharmaceutical won the first evaluation of fosfomycin tromethamine powder is an antibiotic, mainly used for surgical diseases caused by lower urinary tract infections, such as common cystitis, urinary tract inflammation and other diseases
.
According to Minai.
com data, in 2021, the sales of fosfomycin tromethamine scattered in urban public hospitals of Warner Pharmaceutical were 120 million yuan, a year-on-year increase of 38.
40%, with a large market share, and the product has greater future growth potential after winning the first evaluation
.
Bismuth potassium citrate capsules are used for chronic gastritis and relieve stomach pain, heartburn (heartburn) and acid
reflux caused by excessive stomach acidity.
According to data from Minai.
com, in 2019, the terminal sales of this product in China's public medical institutions have exceeded 150 million yuan
.
In addition, Warner Pharmaceutical also submitted supplementary applications
for consistency evaluation of ferrous succinate tablets, lipoic acid injection, nifedipine sustained-release tablets, ornidazole injection and other products.
At present, ferrous succinate tablets have been evaluated, and lipoic acid injection, nifedipine sustained-release tablets, ornidazole injection, etc.
are also on the way
to evaluation.
Under the background of the normalization of centralized procurement, drug evaluation has become the "admission ticket"
for pharmaceutical enterprises to participate in centralized procurement.
At present, Warner Pharmaceutical's winning bid for national centralized procurement products include montmorillonite powder, polyethylene glycol 4000 powder, and mycophenolate capsules
.
In addition, acetylcysteine solution for inhalation, lansoprazole enteric-coated tablets, pediatric calcium carbonate D3 granules, metformin glipizide tablets, nifedipine sustained-release tablets, colloidal pectin bismuth capsules and other varieties have also won the bid for local alliance procurement
.
Through the principle of price for volume, centralized procurement has also brought sustained and stable revenue growth
to Warner Pharmaceutical.
According to the third quarter report of 2022, the company's main revenue in the first three quarters was 927 million yuan, a year-on-year increase of 14.
97%; net profit attributable to owners was RMB124 million, up 20.
22% year-on-year; Non-net profit was RMB108 million, up 18.
03% year-on-year; Among them, in the third quarter of 2022, the company's main revenue in a single quarter was 335 million yuan, a year-on-year increase of 16.
68%; The net profit attributable to the parent in a single quarter was 40.
3214 million yuan, an increase of 18.
26%
over the same period last year.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.